Schwabe News Volume 3| Issue 1 | February 2012
Ignatia amara (Ignatia), a remedy made from the Strychnos ignatii seeds, is used in homoeopathy for depression and anxiety-related symptoms. But consistent scientific study based on modern research parameters of its activity in reproducible experimental models is lacking. This investigation was performed in order to assess on mice, by means of emotional response models, the activity of homoeopathic Ignatia dilutions/dynamizations.
The procedure involved groups of 8 mice of the CD1 albino strain were treated intraperitoneally for 9 days with 0.3 ml of five centesimal (C) dilutions/dynamizations of Ignatia (4C, 5C, 7C, 9C and 30C). Control mice were treated with the same hydroalcoholic (0.3%) solution used to dilute the medicines. Diazepam (1 mg/kg) was the positive reference drug. Validated test models for locomotion and emotional response, the Open-Field (OF) and the Light–Dark (LD) tests, were employed. Five replications of the same protocol were carried out, in a randomised way using coded drugs/controls.
The results showed that in the OF the general locomotion of mice was slightly decreased by Ignatia 4C, but not by Ignatia 5C, 7C, 9C and 30C, indicating the absence of unspecific motor impairment or sedation by these dilutions/dynamizations. Ignatia and diazepam seemed to decrease the number of urine spots released in the OF during 10 min, with borderline significance (P = 0.083). In the LD the tested medicine showed anxiolytic-like activity (increase of time spent and distance travelled in the lit area), though to a lesser extent than diazepam. The highest and most significant difference with untreated controls (P < 0.01) was observed with the 9C dilution/dynamization. Among the 5 replication experiments, the best drug effects were obtained where the baseline anxiety of mice was higher.
The results have lead the researchers to conclude that homoeopathic Ignatia dilutions/dynamizations (peak at 9C) modify some emotion-related symptoms in laboratory mice without affecting locomotion.
The authors present 3 cases of various pathologically confirmed malignancies (one gallbladder, one periampullary, and one liver). These patients underwent the so-called Psorinum therapy as the primary cancer treatment. Psorinum therapy is a name coined by these authors for this specific type of homoeopathic approach to treat patients with cancer.
According to the American Joint Committee on Cancer tumor, nodes, metastasis system, all 3 patients were diagnosed at Stage IV. Their Karnofsky performance status was between 20% and 50% and their Eastern Cooperative Oncology Group score status was between 3 and 4. In these cases, conventional cancer treatments could not be initiated due to the advanced stage of their disease, poor general health performance status, and their financial constraints.
In these patients, Psorinum 6x was administered orally at a dose of 0.02mL/kg body weight/day on an empty stomach for a complete course duration of 2 years, along with allopathic and homoeopathic supportive treatment. According to the Response Evaluation Criteria in Solid Tumors criteria, complete tumor response occurred in 1 case and partial tumor response occurred in the other 2 cases. All 3 patients remained alive and maintained a stable quality of life for at least 2 years. The patients reported no adverse side-effects from Psorinum 6x.
The authors have concluded that this report indicates the clinical efficacy of Psorinum therapy in treating those 3 patients. Thorough basic research and well-designed clinical trials should be conducted for further investigation of this homoeopathic cancer treatment in order to integrate it into the mainstream of oncology treatments.
The information provided herein is not intended to be taken as a replacement for medical advice and should not be used during any medical emergency. A Registered Medical Practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only and they do not constitute endorsements of those other sites.
If you want to receive regular e-mail updates, you can directly subscribe now.
Copyright 2013.Dr. Willmar Schwabe India Pvt. Ltd.. All Rights Reserved.